Alloksys announces first patients enrolled in the continuation of the APPIRED III clinical trial with RESCAP® in patients undergoing cardiothoracic surgery
October 1, 2024. Alloksys anticipates that in the just started continuation of the APPIRED III study (a placebo-controlled combined phase IIb / III trial), with longer administration of RESCAP® (up to 96 hours), benefits such as accelerated recovery and reduced acute kidney injury (AKI) is expected in all patients with underlying Chronic Kidney Disease (CKD) […]
Alloksys announces the enrollment of the first patients in the APhIRI II study with Alkaline phosphatase treatment of patients undergoing kidney transplantation from a deceased donor
July 1-2024. Alloksys anticipates that a treatment with RESCAP® reduces the immediate complications resulting from the kidney transplantation procedure and improves the long-term graft survival. Introduction An important determinant of graft survival is ischemia reperfusion injury. Ischemia and sequential reperfusion are inherent consequences of any transplantation procedure, in particular when the transplanted kidney is donated […]
Alloksys reports interim results of its clinical phase IIb trial with Alkaline Phosphatase therapy RESCAP® in critical care patients
Wageningen, the Netherlands, 24 August 2023 – Alloksys Life Sciences, a clinical stage biotech company specializing in the development of critical care medicines, today announced interim results from its APPIRED-III study. The phase IIb trial focused on evaluating the efficacy of RESCAP® (REScuing Alkaline Phosphatase) in 271 patients undergoing cardiothoracic surgery. The results demonstrate a […]
JANUARY 2020 APPIRED III – 9 INTERNATIONAL CENTRES AND MORE TO COME
APPIRED III study is getting well on its way with 9 centres started with including patients. These centres are Singapore NUH, CZE Eindhoven, Jessa, Hasselt, UniMed Wien Vienna, Almazov Heart Centre St Petersburg and IJN Kuala Lumpur. Recently Monash Melbourne, AZM Middelares, Gent, MUMC Maastricht were added. Four additional centers in St Petersburg and Kazan […]
UPDATE DECEMBER 2019: SOLID ORGAN TRANSPLANTATION STUDY WELL ON ITS WAY
After approval was obtained in October 2018, the kidney transplantation study with RESCAP platform technology under supervision of PI Dr Joost van der Heijden from VUmc Amsterdam found its “First Patient In” status in June 2019. Ischemic injury in kidneys to be transplanted are cause of serious complications and limit overall success rate of transplantation. […]
SISTER COMPANY AMRIF READYING UP FOR CLINICAL TRIAL IN CHRONIC INFLAMMATORY DISEASE
AMRIF, Alloksys’s sister company is readying up for trials in several chronic inflammatory disease applications. Among these diseases are unmet medical need applications in Neurodegenerative diseases Parkinson and Alzheimer as well in several complications from diabetes. Protocols, clinicians, clinical centers, specialty institutes and patients have committed to participate in these studies. The studies will start […]
APPIRED III STARTED RECRUITMENT IN ASIA AT NUHCS, SINGAPORE
Following the start of patient inclusion in Europe, the first Asian center participating international study APPIRED lll has started patient recruitment. The National University Heart Centre, Singapore (NUHCS) is the country’s national heart specialty Centre. It is also taking international leadership in this trial, led by principal investigator Professor Theodoros Kofidis MD, PhD. The objective […]
